CDKN2T

Shibo Wei1, Yan Zhang2, Baeki E Kang3

  • 1Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.

BMB reports
|March 25, 2024
PubMed
概括

循环素依赖性激酶抑制剂2 (CDKN2) 显示为肝细胞癌 (HCC) 进展的生物标志物具有前途. CDKN2表达与T细胞枯竭相关,有助于个性化HCC免疫疗法.